SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
Creative collage illustration of financial business. Two businessmen shaking hands for partners agreement. Conceptual illustration of success deal, corporate ethic, connection.
Collaboration
Kite Makes $1.5B+ Cell Therapy Pact With Pregene as Others Pull Back
With more than $1.5 billion on the line, Gilead looks to bolster its CAR T portfolio.
October 17, 2025
 · 
2 min read
 · 
Tristan Manalac
Health saving account, HSA, financial plan saving for medical expense or medicare cost and benefits concept, doctor with stethoscope standing with huge pink piggy bank or coin bank with medical sign.
Drug pricing
In Affordability Push, EMD Serono Joins TrumpRx While Roche Launches DTC Program
EMD Serono will offer its fertility treatments on TrumpRx at a steep discount, and Roche’s direct-to-consumer offering will cover its flu pill Xofluza.
October 17, 2025
 · 
2 min read
 · 
Tristan Manalac
REGULATORY
Webinar: Shifting Risk | Biopharma in an Age of Deregulation
During this webinar BioSpace sits down with former FDA Chief Information Officer Vid Desai to discuss the potential advantages and pitfalls of deregulation stemming from one of President Donald Trump’s first executive orders. Together, they uncover what this shift means for drugmakers, compliance and patient safety.
October 16, 2025
 · 
1 min read
 · 
Jef Akst
IN PARTNERSHIP WITH PII
Work Smart, Build Trust: Connecting Technology, Patient Compliance and Data Processing
In this episode presented by PII, BioSpace’s head of insights discusses decentralized clinical studies and how connected technology can improve patient compliance with guests Oliver Eden and Travis Webb.
October 16, 2025
 · 
1 min read
 · 
BioSpace Insights
Gentilly, France, March 21, 2021: Exterior view of the Sanofi headquarters building. Sanofi is a French multinational company specializing in the health sector
Autoimmune disease
Sanofi Joins With EVOQ in $500M Autoimmune Alliance
The partners have yet to disclose what their priority indications are, though EVOQ’s NanoDisc technology aims to enable the development of potentially curative treatments for autoimmune conditions such as celiac disease and type 1 diabetes.
October 16, 2025
 · 
2 min read
 · 
Tristan Manalac
Human resource management and recruitment concept. Job rotation or staff turnover icon.
Government
FDA’s Orphan Drug Director Out Amid IRA Exemption Rollout
An unnamed source clarified that Sandra Retzky has not been fired from the FDA, but it remains unclear where she was reassigned.
October 16, 2025
 · 
2 min read
 · 
Tristan Manalac
3D illustration of hair root growing from skin cells, symbolizing strength, growth, and nourishment. Perfect for haircare, cosmetic advertising, medical research, and healthcare concepts.
Funding
Veradermics Gets $150M Series C To Advance Hair Regrowth Pill
Veradermics is the second hair regrowth specialist to fundraise this week, after Pelage Pharmaceuticals announced Wednesday it had brought in $120 million for its own therapy.
October 16, 2025
 · 
2 min read
 · 
Tristan Manalac
Job Trends
Report: U.S. Life Sciences Job Market Report Q3 2025
BioSpace’s Q3 2025 U.S. Life Sciences Job Market Report reveals a turbulent quarter for biopharma hiring, with record declines in job postings, rising layoffs, and cautious employer sentiment shaping the industry’s employment landscape.
October 16, 2025
 · 
1 min read
 · 
BioSpace Insights
Illustration showing three businesspeople hanging on the edge of a cliff
Layoffs
Q3 Layoffs Up 280% YOY With CSL, Merck, Novo’s Restructurings
Due largely to CSL, Merck and Novo Nordisk’s reorganizations that could total about 19,350 people, Q3 cuts rose significantly year over year and quarter over quarter, based on BioSpace tallies.
October 16, 2025
 · 
4 min read
 · 
Angela Gabriel
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS